Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 2Efficacy & side effects

2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Other(1)

Detailed Status

Terminated1

unknown1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

terminated133%

unknown133%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

unknown

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NCT04930133

completedphase_2

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NCT02747953

terminatedphase_2

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

NCT02541903

Clinical Trials (3)

Showing 3 of 3 trials

NCT04930133

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

Unknown

NCT02747953Phase 2

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Completed

NCT02541903Phase 2

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3